Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1996-08-30
1999-06-08
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4352351, 435236, 4242011, A61K 39155, A61K 39295, C12N 700
Patent
active
059103108
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a viral agent, processes for the culture and replication of this agent and the utilization of this agent on its own or in combination with other bacterial or viral pathogens as a vaccine component for the protection of pigs from diseases of the respiratory and reproductive tract.
At the end of the eighties to the start of the nineties a new pig disease which spread like the plague and was accompanied by high economic losses occurred in North America and Europe. In the meantime, this has been officially called "Porcine Reproductive and Respiratory Syndrome" (PRRS).
The main clinical symptoms of these contagious diseases are fertility disorders in sows and respiratory tract diseases in piglets and fattening pigs.
Besides the irregularly occurring non-specific symptoms such as loss of appetite, apathy and fever, the disease is characterized in sows by late abortions, stillbirths and by the birth of mummified and weak piglets. As a result of the epidemic, symptoms of the mastitis-metritis-agalactia (MMA) complex and return to oestrus occur in large numbers.
In an endemic region are unweaned and weaner piglets in an endemic region are mainly affected at the start of the epidemic, in the further course fattening pigs increasingly fall ill. In this case, besides the mainly occurring diseases of the respiratory tract, other classical pig diseases can also be observed in association at an increased frequency. The epidemic causes considerable economic losses, which results besides the direct animal losses from the decrease in the characteristic production numbers (farrowing and weaning results, pregnancy rate, weight increase).
The primary infectious agent is assumed to be a new RNA virus replicating in pulmonary alveolar macrophages. On the other hand, epidemiological investigations indicate that respiratory and reproductive diseases can be additionally caused or intensified by secondary or multiple infections with other viruses or viruses and bacteria. It is therefore desirable to protect pigs not only against the main causative agent of PRRS, but also against the causative agents which are additionally responsible for respiratory and reproductive diseases.
The present invention relates to: pigs, in particular in connection with the disease complex called PRRS, characterized by containing as antigenic material, in whole form or in parts or submits parainfluenza viruses and their variants and mutants in modified live or inactivated form, prepared by conventional or recombinant techniques. respiratory and reproductive tract of pigs. which cause diseases of the respiratory and reproductive tract of pigs, characterized in that parainfluenza viruses are replicated and the antigenic material is isolated in a manner known per se from the virus suspensions thus obtained of the respiratory and reproductive tract of pigs for the diagnosis and/or prevention of these diseases. of the respiratory and reproductive tract of pigs for the production of diagnostics for the detection of these diseases and for the production of vaccines for the prevention of these diseases.
Antigenic material which may be mentioned is: cell cultures or embryonated chicken eggs. passages of the virus in primary cell cultures, permanent cell lines, embryonated poultry eggs or experimental animals with subsequent replication in cell cultures or embryonated chicken eggs. conventional processes, such as chemical or physical inactivation. in cell cultures or embryonated eggs. the means of recombinant techniques and can optionally be separated from these or isolated from these. genome of the virus or parts thereof employed by means of recombinant techniques in genome vectors such as vaccini viruses, herpes viruses, adenoviruses or other suitable vector systems.
Parainfluenza viruses type 2 (PIV-2) are preferably used. PIV-2 which have been isolated from the respiratory or reproductive tract of pigs which exhibit a PRRS-like symptomatology are particularly preferred. The PIV-2 strain having the notation SER, which was deposit
REFERENCES:
Chanock et al Parainfluenza virus in Virology Ed Fields Raven Press New York p. 1250, 1985.
Itoh et al. Single amino substitution of sendai virus at the cleavage site of the fusion confers trypsin resistance. J. Gen. Virology 68:2939-2944, 1987.
Christianson, W.T. et al. Swine Health and Production, vol. 2, No. 2, p. 10-28, Apr. 1994.
Crandell, R.A. et al. Journal of Clinical Microbiology, vol. 7, No. 2, pp. 214-218, Feb. 1978.
Fenner, F.J. et al. Veterinary Virology, second edition, pp. 476-478. Academic Press, Inc., San Diego CA, 1993.
Goyal, S.M. et al. The Veterinary Record, vol. 119, No. 14, p. 363, Oct. 1986.
Guenov, I. et al. Zentralblatt fur Veterinarymedizin, vol. 19B (Heft 6), pp. 437-444, abstract only, 1972.
Hernandez Jauregui, P. et al. Veterinaria Mexico, vol. 23, pp. 217-222, abstract only, 1992.
The Veterinary Record, vol. 129, No. 1, p. 19, London Jul. 6, 1991.
Heinen Ernst
Herbst Werner
Schmeer Norbert
Bayer Aktiengesellschaft
Gil Joseph C.
Mosher Mary E.
LandOfFree
Porcine parainfluenza virus type 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porcine parainfluenza virus type 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porcine parainfluenza virus type 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1682160